JP2025016545A5 - - Google Patents
Info
- Publication number
- JP2025016545A5 JP2025016545A5 JP2024186222A JP2024186222A JP2025016545A5 JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5 JP 2024186222 A JP2024186222 A JP 2024186222A JP 2024186222 A JP2024186222 A JP 2024186222A JP 2025016545 A5 JP2025016545 A5 JP 2025016545A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- linker
- payload conjugate
- payload
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19163810 | 2019-03-19 | ||
| EP19163810.5 | 2019-03-19 | ||
| JP2022504337A JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| PCT/EP2020/057697 WO2020188061A1 (en) | 2019-03-19 | 2020-03-19 | Transglutaminase conjugation method with a glycine based linker |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Division JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025016545A JP2025016545A (ja) | 2025-02-04 |
| JP2025016545A5 true JP2025016545A5 (cg-RX-API-DMAC7.html) | 2025-10-21 |
Family
ID=65903991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Active JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
| JP2024186222A Pending JP2025016545A (ja) | 2019-03-19 | 2024-10-22 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504337A Active JP7629902B2 (ja) | 2019-03-19 | 2020-03-19 | グリシンベースリンカーを用いたトランスグルタミナーゼコンジュゲーション法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220133904A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3941526A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7629902B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220144753A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113613679A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020243056A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3128571A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020188061A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018337671B2 (en) | 2017-09-19 | 2021-03-04 | Paul Scherrer Institut | Transglutaminase conjugation method and linker |
| EP3980080A1 (en) * | 2019-06-10 | 2022-04-13 | Sutro Biopharma, Inc. | Immunomodulator antibody drug conjugates and uses thereof |
| CN114845740B (zh) | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| US20230095053A1 (en) * | 2020-03-03 | 2023-03-30 | Sutro Biopharma, Inc. | Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use |
| EP4213886A1 (en) * | 2020-09-18 | 2023-07-26 | Araris Biotech AG | Transglutaminase conjugation method with amino acid-based linkers |
| CN116801910A (zh) * | 2020-10-25 | 2023-09-22 | 阿拉里斯生物技术股份公司 | 生产抗体-接头偶联物的手段和方法 |
| JP7789396B2 (ja) * | 2020-10-25 | 2025-12-22 | アラリス バイオテック アーゲー | 抗体-リンカーコンジュゲートを生成するための手段および方法 |
| JP2024501121A (ja) | 2020-11-25 | 2024-01-11 | イナート・ファルマ・ソシエテ・アノニム | 癌の処置 |
| AU2021389027A1 (en) * | 2020-11-30 | 2023-06-29 | Anbition S.R.L. | Multi-specific human albumin nanoparticles decorated with antibody fragments and loaded with cytotoxics |
| AU2022307460A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Checkpoint inhibitors conjugated to il-2, and uses thereof |
| AU2022306788A1 (en) | 2021-07-09 | 2024-01-04 | Bright Peak Therapeutics Ag | Conjugates of checkpoint inhibitors with il-2, and uses thereof |
| US20230201364A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
| WO2023281482A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Cd20-targeted il-2 and its uses |
| KR20240034221A (ko) | 2021-07-09 | 2024-03-13 | 브라이트 피크 테라퓨틱스 아게 | 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드 |
| AU2022318483A1 (en) * | 2021-07-28 | 2024-02-22 | Merck Patent Gmbh | Water soluble prodrug, conjugates and uses thereof |
| JP2025505835A (ja) * | 2022-02-22 | 2025-02-28 | アーデーセー セラピューティクス ソシエテ アノニム | トリミングされたn-グリカンを含むfc領域でのトランスグルタミナーゼを伴うコンジュゲーション方法 |
| KR20240150807A (ko) | 2022-02-22 | 2024-10-16 | 아라리스 바이오테크 아게 | 2개 이상의 페이로드를 포함하는 펩티드 링커 |
| AU2023226512A1 (en) | 2022-02-23 | 2024-08-29 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
| EP4489862A1 (en) | 2022-03-09 | 2025-01-15 | Merck Patent GmbH | Anti-ceacam5 antibodies and conjugates and uses thereof |
| WO2023227660A1 (en) | 2022-05-25 | 2023-11-30 | Innate Pharma | Nectin-4 binding agents |
| CN119998325A (zh) | 2022-08-08 | 2025-05-13 | Atb治疗公司 | 抗CD79b的人源化抗体 |
| CN115814111B (zh) * | 2022-12-05 | 2025-03-28 | 复旦大学附属中山医院 | 一种近红外荧光adc免疫制剂及其制备方法与应用 |
| WO2024150174A1 (en) | 2023-01-11 | 2024-07-18 | Bright Peak Therapeutics Ag | Conditionally activated immunocytokines and methods of use |
| US20240424127A1 (en) | 2023-01-11 | 2024-12-26 | Bright Peak Therapeutics Ag | Il-7 polypeptides, immunocytokines comprising same, and uses thereof |
| CN116077676B (zh) * | 2023-02-03 | 2025-09-12 | 南京大学 | 蛋白质靶向降解嵌合体及其制备方法和应用 |
| EP4665378A2 (en) * | 2023-02-14 | 2025-12-24 | Georgia State University Research Foundation, Inc. | Anti-angiogenic agent and methods of using such agent |
| WO2025041101A1 (en) | 2023-08-23 | 2025-02-27 | Bright Peak Therapeutics Ag | Activatable il-18 immunocytokines and uses thereof |
| US20250186597A1 (en) | 2023-08-23 | 2025-06-12 | Bright Peak Therapeutics Ag | Targeted immune activation with il-18 immunocytokines |
| WO2025082990A1 (en) | 2023-10-15 | 2025-04-24 | Araris Biotech Ag | Antibody-drug conjugates using two different types of topoisomerase i inhibitors |
| WO2025192692A1 (ja) * | 2024-03-14 | 2025-09-18 | 東レ株式会社 | 癌の治療及び/又は予防用医薬組成物 |
| WO2026008881A1 (en) | 2024-07-05 | 2026-01-08 | Synaffix B.V. | Extracellular vesicles comprising biomolecule-conjugates |
| WO2026013234A1 (en) | 2024-07-10 | 2026-01-15 | Araris Biotech Ag | Triple-payload antibody-drug conjugates (adcs) |
| WO2026024870A1 (en) * | 2024-07-23 | 2026-01-29 | Sparx Bioscience Limited | Peptide linkers for construction and reducing aggregation of fusion polypeptides comprising such |
| WO2026069134A1 (en) | 2024-09-26 | 2026-04-02 | Bright Peak Therapeutics Ag | Human therapy with il-18 immunocytokines |
| WO2026083296A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains |
| WO2026083295A1 (en) | 2024-10-16 | 2026-04-23 | Bright Peak Therapeutics Ag | Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| EP2123756B1 (en) | 2007-02-15 | 2014-06-04 | Ajinomoto Co., Inc. | Transglutaminase having disulfide bond introduced therein |
| WO2008102007A1 (en) | 2007-02-22 | 2008-08-28 | Novo Nordisk Health Care Ag | Transglutaminase variants with improved specificity |
| CA2813411C (en) * | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| EP2777714A1 (en) * | 2013-03-15 | 2014-09-17 | NBE-Therapeutics LLC | Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme |
| US10195289B2 (en) | 2013-07-31 | 2019-02-05 | Rinat Neuroscience Corp. | Engineered polypeptide conjugates using transglutaminase |
| KR20190072663A (ko) * | 2014-04-25 | 2019-06-25 | 리나트 뉴로사이언스 코프. | 약물이 고도로 로딩된 항체-약물 접합체 |
| CA2951887A1 (en) * | 2014-06-12 | 2015-12-17 | Cspc Dophen Corporation | Homogenous antibody drug conjugates via enzymatic methods |
| CA2971246C (en) | 2014-12-19 | 2020-07-14 | F. Hoffmann-La Roche Ag | Identification of transglutaminase substrates and uses therefor |
| ES2871624T3 (es) | 2014-12-19 | 2021-10-29 | Hoffmann La Roche | Transglutaminasas microbianas, sustratos para las mismas y procedimientos para el uso de las mismas |
| US20180028682A1 (en) * | 2015-02-09 | 2018-02-01 | Nbe Therapeutics Ag | Maytansine-drug conjugates of her-2 specific binding proteins generated by site specific sortase-enzyme mediated conjugation |
| ES2736106T3 (es) | 2015-03-10 | 2019-12-26 | Bristol Myers Squibb Co | Anticuerpos que se pueden conjugar mediante la transglutaminasa y conjugados producidos a partir de ellos |
| WO2017025179A1 (en) | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| KR20230008269A (ko) * | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
-
2020
- 2020-03-19 CN CN202080022652.9A patent/CN113613679A/zh active Pending
- 2020-03-19 CA CA3128571A patent/CA3128571A1/en active Pending
- 2020-03-19 KR KR1020217033833A patent/KR20220144753A/ko active Pending
- 2020-03-19 WO PCT/EP2020/057697 patent/WO2020188061A1/en not_active Ceased
- 2020-03-19 US US17/435,356 patent/US20220133904A1/en active Pending
- 2020-03-19 JP JP2022504337A patent/JP7629902B2/ja active Active
- 2020-03-19 AU AU2020243056A patent/AU2020243056A1/en active Pending
- 2020-03-19 EP EP20711197.2A patent/EP3941526A1/en active Pending
-
2024
- 2024-10-22 JP JP2024186222A patent/JP2025016545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022525704A5 (cg-RX-API-DMAC7.html) | ||
| US20200289661A1 (en) | Cd48 antibodies and conjugates thereof | |
| JP7239558B2 (ja) | テトラマレイミドリンカー及びその使用 | |
| JP7815223B2 (ja) | 可溶性タグを有する分子および関連方法 | |
| JP2020534030A5 (cg-RX-API-DMAC7.html) | ||
| EP3695852A1 (en) | Anti-mesothelin antibody and antibody-drug conjugate thereof | |
| PL172837B1 (pl) | Preparat farmaceutyczny zawierajacy koniugaty tioeterowe PL PL PL PL PL | |
| CN110240654A (zh) | 结合cd73的抗体-药物偶联物 | |
| KR20230008723A (ko) | 전하 변이체 링커 | |
| JP2018523471A5 (cg-RX-API-DMAC7.html) | ||
| US20190298846A1 (en) | Cell targeting conjugates | |
| JP2020510656A5 (cg-RX-API-DMAC7.html) | ||
| JP2023546493A5 (cg-RX-API-DMAC7.html) | ||
| JP2023529640A (ja) | 治療用コンジュゲート | |
| JP2023522392A (ja) | 抗ceacam5抗体コンジュゲートおよびフォルフィリを含有する抗腫瘍組み合わせ | |
| JP2024539989A5 (cg-RX-API-DMAC7.html) | ||
| JP2023522396A (ja) | 抗ceacam5抗体コンジュゲート、トリフルリジン、およびチピラシルを含有する抗腫瘍組み合わせ | |
| JP2023542910A5 (cg-RX-API-DMAC7.html) | ||
| JP2024542095A5 (cg-RX-API-DMAC7.html) | ||
| EP3684412A1 (en) | Methods of preventing methionine oxidation in immunoconjugates | |
| NZ779213B2 (en) | Transglutaminase conjugation method with a glycine based linker | |
| NZ779213A (en) | Transglutaminase conjugation method with a glycine based linker | |
| CN101277716A (zh) | 治疗癌症的抗体 | |
| WO2025003392A1 (en) | Bioconjugation systems and uses thereof | |
| WO2025194123A1 (en) | Muc16/napi-2b antibodies and methods of use |